Corcept Therapeutics annual revenue
2009
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Corcept Therapeutics Revenue Growth & History (CORT)
Corcept Therapeutics reported $761.4M in revenue for fiscal 2025, an increase of 12.79% from the previous fiscal year.
View full Corcept Therapeutics company overviewCorcept Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $761.4M | $86.4M | +12.79% |
| 2024 | 2024-12-31 | $675.0M | $192.7M | +39.94% |
| 2023 | 2023-12-31 | $482.4M | $80.5M | +20.04% |
| 2022 | 2022-12-31 | $401.9M | $35.9M | +9.80% |
| 2021 | 2021-12-31 | $366.0M | $12.1M | +3.42% |
| 2020 | 2020-12-31 | $353.9M | $47.4M | +15.46% |
| 2019 | 2019-12-31 | $306.5M | $55.2M | +21.99% |
| 2018 | 2018-12-31 | $251.2M | $92.0M | +57.82% |
| 2017 | 2017-12-31 | $159.2M | $77.9M | +95.77% |
| 2016 | 2016-12-31 | $81.3M | $31.0M | +61.72% |
| 2015 | 2015-12-31 | $50.3M | $23.7M | +89.39% |
| 2014 | 2014-12-31 | $26.6M | $16.2M | +156.36% |
| 2013 | 2013-12-31 | $10.4M | $7.0M | +213.18% |
| 2012 | 2012-12-31 | $3.3M | — | — |
| 2009 | 2009-12-31 | $29,000 | — | — |
Corcept Therapeutics quarterly revenue
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $256.1M | $61.7M | +31.74% |
| Q1 2026 | 2026-03-31 | $164.9M | $7.7M | +4.89% |
| Q4 2025 | 2025-12-31 | $202.1M | $20.2M | +11.12% |
| Q3 2025 | 2025-09-30 | $207.6M | $25.1M | +13.75% |
| Q2 2025 | 2025-06-30 | $194.4M | $30.6M | +18.70% |
| Q1 2025 | 2025-03-31 | $157.2M | $10.4M | +7.09% |
| Q4 2024 | 2024-12-31 | $181.9M | $46.5M | +34.33% |
| Q3 2024 | 2024-09-30 | $182.5M | $58.9M | +47.69% |
| Q2 2024 | 2024-06-30 | $163.8M | $46.1M | +39.15% |
| Q1 2024 | 2024-03-31 | $146.8M | $41.2M | +38.95% |
| Q4 2023 | 2023-12-31 | $135.4M | $32.3M | +31.39% |
| Q3 2023 | 2023-09-30 | $123.6M | $21.9M | +21.50% |
| Q2 2023 | 2023-06-30 | $117.7M | $14.3M | +13.86% |
| Q1 2023 | 2023-03-31 | $105.7M | $12.0M | +12.77% |
| Q4 2022 | 2022-12-31 | $103.1M | $4.2M | +4.28% |
| Q3 2022 | 2022-09-30 | $101.7M | $5.6M | +5.82% |
| Q2 2022 | 2022-06-30 | $103.4M | $11.8M | +12.88% |
| Q1 2022 | 2022-03-31 | $93.7M | $14.3M | +17.94% |
| Q4 2021 | 2021-12-31 | $98.8M | $13.1M | +15.26% |
| Q3 2021 | 2021-09-30 | $96.1M | $9.8M | +11.36% |
| Q2 2021 | 2021-06-30 | $91.6M | $3.0M | +3.41% |
| Q1 2021 | 2021-03-31 | $79.4M | −$13.8M | −14.81% |
| Q4 2020 | 2020-12-31 | $85.7M | −$2.2M | −2.46% |
| Q3 2020 | 2020-09-30 | $86.3M | $4.8M | +5.92% |
| Q2 2020 | 2020-06-30 | $88.6M | $16.3M | +22.57% |
| Q1 2020 | 2020-03-31 | $93.2M | $28.4M | +43.84% |
| Q4 2019 | 2019-12-31 | $87.9M | $21.1M | +31.52% |
| Q3 2019 | 2019-09-30 | $81.5M | $17.1M | +26.47% |
| Q2 2019 | 2019-06-30 | $72.3M | $9.9M | +15.96% |
| Q1 2019 | 2019-03-31 | $64.8M | $7.2M | +12.44% |
| Q4 2018 | 2018-12-31 | $66.8M | $13.6M | +25.43% |
| Q3 2018 | 2018-09-30 | $64.4M | $21.7M | +50.70% |
| Q2 2018 | 2018-06-30 | $62.3M | $26.8M | +75.24% |
| Q1 2018 | 2018-03-31 | $57.7M | $30.1M | +108.92% |
| Q4 2017 | 2017-12-31 | $53.3M | $29.5M | +123.76% |
| Q3 2017 | 2017-09-30 | $42.8M | $21.0M | +96.84% |
| Q2 2017 | 2017-06-30 | $35.6M | $15.8M | +80.28% |
| Q1 2017 | 2017-03-31 | $27.6M | $11.5M | +71.84% |
| Q4 2016 | 2016-12-31 | $23.8M | $8.8M | +59.09% |
| Q3 2016 | 2016-09-30 | $21.7M | $8.5M | +63.83% |
| Q2 2016 | 2016-06-30 | $19.7M | $7.8M | +64.97% |
| Q1 2016 | 2016-03-31 | $16.1M | $6.0M | +58.99% |
| Q4 2015 | 2015-12-31 | $15.0M | $6.0M | +66.06% |
| Q3 2015 | 2015-09-30 | $13.3M | $6.0M | +82.11% |
| Q2 2015 | 2015-06-30 | $12.0M | $6.1M | +104.34% |
| Q1 2015 | 2015-03-31 | $10.1M | $5.7M | +129.33% |
| Q4 2014 | 2014-12-31 | $9.0M | $4.9M | +119.03% |
| Q3 2014 | 2014-09-30 | $7.3M | $4.6M | +176.46% |
| Q2 2014 | 2014-06-30 | $5.9M | $4.0M | +209.41% |
| Q1 2014 | 2014-03-31 | $4.4M | $2.7M | +156.55% |
| Q4 2013 | 2013-12-31 | $4.1M | $2.7M | +198.84% |
| Q3 2013 | 2013-09-30 | $2.6M | $1.6M | +149.67% |
| Q2 2013 | 2013-06-30 | $1.9M | $1.0M | +116.11% |
| Q1 2013 | 2013-03-31 | $1.7M | — | — |
| Q4 2012 | 2012-12-31 | $1.4M | — | — |
| Q3 2012 | 2012-09-30 | $1.1M | — | — |
| Q2 2012 | 2012-06-30 | $875,000 | — | — |
Corcept Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue grew from $353.9M to $761.4M, a compound annual growth rate of 16.56%. Corcept Therapeutics's latest reported quarter, Q2 2026, generated $256.1M in revenue, an increase of 31.74% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Corcept Therapeutics source filings ↗Community posts
Corcept receives positive European recommendation for ovarian-cancer therapy
European drug advisers recommended approval of Corcept’s ($CORT) relacorilant, to be marketed as Lifyorli, in combination with nab-paclitaxel for platinum-resistant ovarian cancer. The positive opinion from the Committee for Medicinal Produ ...
